HC Wainwright Reaffirms “Hold” Rating for Aviragen Therapeutics, Inc. (AVIR)
Aviragen Therapeutics, Inc. (NASDAQ:AVIR)‘s stock had its “hold” rating restated by analysts at HC Wainwright in a research report issued on Monday.
Aviragen Therapeutics (NASDAQ AVIR) opened at $0.58 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.76 and a quick ratio of 6.76. Aviragen Therapeutics has a one year low of $0.43 and a one year high of $1.60.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu KCG Holdings LLC bought a new stake in Aviragen Therapeutics during the 2nd quarter worth about $149,000. FMR LLC lifted its position in Aviragen Therapeutics by 0.3% during the 2nd quarter. FMR LLC now owns 1,005,345 shares of the biotechnology company’s stock worth $673,000 after buying an additional 2,845 shares in the last quarter. Finally, Carlson Capital Management bought a new stake in Aviragen Therapeutics during the 2nd quarter worth about $105,000. 24.20% of the stock is owned by hedge funds and other institutional investors.
About Aviragen Therapeutics
Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals, Inc, is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options.
Receive News & Ratings for Aviragen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aviragen Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.